The FDA rejected Replimune Group’s oncolytic virus therapy for advanced melanoma for a second time, according to separate coverage of the agency’s latest decision. The company’s therapy, vusolimogene oderparepvec (RP-1), failed to address the regulator’s prior issues around the study results, the FDA said. The decision renews scrutiny over evidentiary thresholds for immune-stimulating viral approaches.